发布时间:
2018
-
05
-
11
点击次数:
0
Positions：
Partner
Company：
GlobalLaw’s Shanghai Office
个人简介：
Alan Zhou is a partner at Global Law’s Shanghai Office. His practice is focused in the areas of mergers & acquisitions, private equity/venture capital, general corporate, and regulatory compliance. Mr. Zhou has represented many multinational corporations, reputable Chinese state owned and private corporations, and private equity/venture capital funds in a wide range of industries. As an expert on legal issues surrounding M&A, compliance and anti-corruption and taxes of foreign invested enterprises in China, Mr. Zhou has provided several well-known multinational companies with legal opinions on some of the most challenging aspects of foreign investment in China. Mr. Zhou has a particularly strong background in the Pharmaceutical and Healthcare, and TMT industrial sectors. As the leading partner at Pharmaceutical and Healthcare practice group at Global, Mr. Zhou is praised for his "broad knowledge of the law, deep understanding of the pharmaceutical industry and strong communication skills." –Chambers and Partners . Mr. Zhou has routinely represented such multinational corporations as AstraZenca, Novartis, MSD, GSK, Sanofi, Schlumberger, Boehringer Ingelheim, Siemens, Aon, Bureau Veritas, Tosoh, Societe Generale Bank and SK Telecom. Mr. Zhou not only worked for reputable Chinese private companies such as Focus Media, Acorn International, Hisoar Pharmaceutical, Tianyuan Biopharm, and Yonjin Group, he also advised PRC state owned companies such as Shanghai Dasheng, Shanghai Industrial and Shanghai Airport Authority. In the area of PE/VC, Mr. Zhou has acted for CBRE Investors, Colony Capital, Navis Capital, Lightspeed Ventures, Qiming Ventures, DT Capital, NEA, New Alliance Capital, Warden International, WINS and other international and local investment funds. Mr. Zhou has been worked with Boehringer Ingelheim China as the general counsel in China over nine years and is responsible for various legal matters including general corporate, acquisitions and joint venture formation, regulatory compliance, intellectual property and corporate restructure.